drugset / Trial / NCT00834522

Granisetron 1 mg Tablets, Non-fasting

NCT00834522

Phase 1 Completed 80 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study is to evaluate the comparative bioavailability between granisetron hydrochloride 1 mg tablets (Teva Pharmaceuticals USA) and Kytril® 1 mg tablets (Roche, USA), after a single-dose in health subjects under fed conditions.

Timeline

Start
2005-07
Primary completion
2005-07
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Granisetron Other / unclassified 2 mg

Indications

No indication recorded.